肺癌新希望---FDA昨批准扩大使用Bristol-Myer的Opdivo治疗晚期/转移性鳞状非小细胞肺癌

Bristol-Myer的Opdivo是一种针对PD-1抗体的免疫检查点抑制剂（属于免疫疗法），继上月批准用于皮肤癌后，正在进行中的肺癌临床试验提前终止，因为效果比起对照的taxel好很多。被用于治疗晚期（转移性）鳞状非小细胞肺癌（NSCLC）。希望有更多的临床好结果的陆续报道。

FDA新闻链接: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm436534.htm

The U.S. Food and Drug Administration today expanded the approved use of Opdivo (nivolumab) to treat patients with advanced (metastatic) squamous non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy.

Lung cancer is the leading cause of cancer death in the United States, with an estimated 224,210 new diagnoses and 159,260 deaths in 2014. The most common type of lung cancer, NSCLC affects seven out of eight lung cancer patients, occurring when cancer forms in the cells of the lung.

Opdivo works by inhibiting the cellular pathway known as PD-1 protein on cells that blocks the body’s immune system from attacking cancerous cells. Opdivo is intended for patients who have previously been treated with platinum-based chemotherapy.

......

药品图片和PD-1的作用图（利用PD-1通路的阻断来治疗肿瘤）:

http://immugeek.com/bristol-myers-squibb-announces-multiple-regulatory-milestones-opdivo-nivolumab/

五分钟了解肺癌种类:

Lung cancer types